Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01830205 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT01830205 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 58 participants.
The verdict
NCT01830205, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of renal function impairment on the single dose pharmacokinetics of Daclatasvir.
Interventions
- DRUG Daclatasvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01830205
The ClinicalTrials.gov registry entry for NCT01830205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daclatasvir is the first listed.
NCT01830205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01830205 about?
NCT01830205 is a clinical study titled "Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment". The purpose of this study is to assess the effect of renal function impairment on the single dose pharmacokinetics of Daclatasvir.
What is the current status of trial NCT01830205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2012-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01830205?
The interventions under investigation include: Daclatasvir (DRUG).
Who is sponsoring clinical trial NCT01830205?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.